Drug – bio-affecting and body treating compositions – Whole live micro-organism – cell – or virus containing – Animal or plant cell
Reexamination Certificate
2003-03-07
2009-12-29
Canella, Karen A (Department: 1643)
Drug, bio-affecting and body treating compositions
Whole live micro-organism, cell, or virus containing
Animal or plant cell
C435S070100, C435S377000
Reexamination Certificate
active
07638122
ABSTRACT:
The present invention relates to methods for treating and/or preventing cancer. In particular the present invention relates to ex vivo immunotherapeutic methods. The methods comprise decreasing Stat3 (signal transducer and activator of transcription3) expression and/or function in tumor cells and the administration of such cells to a subject in need of treatment and/or prevention. Other methods of the invention comprise activating T-cells by co-culturing the T-cells with the tumor cells with decreased Stat3 expression or function. The invention further encompasses methods comprising decreasing Stat3 expression or function in antigen-presenting cells and co-administering tumor cells and the antigen-presenting cells with decreased Stat3 function to a patient. The invention further relates to methods for stimulating dendritic cell differentiation.
REFERENCES:
patent: 4690915 (1987-09-01), Rosenberg
patent: 4853380 (1989-08-01), Schwartz
patent: 5045316 (1991-09-01), Kaplan
patent: 5093246 (1992-03-01), Cech et al.
patent: 5159694 (1992-10-01), Overath et al.
patent: 5290551 (1994-03-01), Berd
patent: 5716622 (1998-02-01), Darnell et al.
patent: 5731155 (1998-03-01), Schreiber et al.
patent: 5883228 (1999-03-01), Darnell, Jr. et al.
patent: 5935993 (1999-08-01), Tang et al.
patent: 5972598 (1999-10-01), Chaudhary et al.
patent: 5976835 (1999-11-01), Darnell, Jr. et al.
patent: 6130087 (2000-10-01), Srivastava et al.
patent: 6159694 (2000-12-01), Karras
patent: 6235873 (2001-05-01), Bromberg et al.
patent: 6265160 (2001-07-01), Leonard
patent: 6426366 (2002-07-01), Novogrodsky et al.
patent: 6469013 (2002-10-01), Uckun et al.
patent: 6602709 (2003-08-01), Albert et al.
patent: 7348139 (2008-03-01), Herman et al.
patent: 2002/0155108 (2002-10-01), Barbera-Guillem
patent: 2004/0052762 (2004-03-01), Yu et al.
patent: WO97/26328 (1997-07-01), None
patent: WO 99/28465 (1998-06-01), None
patent: WO 98/30688 (1998-07-01), None
patent: WO 98/41090 (1998-09-01), None
patent: WO99/58126 (1999-11-01), None
patent: 00/44774 (2000-08-01), None
patent: WO02/18572 (2002-03-01), None
patent: WO 02/20032 (2002-03-01), None
Abstract of Wheeler (Salud p'ublica de M'exico, (Jul.-Aug. 1997) 39 (4) 283-7).
Bachman et al (Journal of Immunology, 2005, vol. 175, pp. 4677-4685).
Todryk et al (Immunology, 2000, vol. 99, pp. 334-337).
Efferson et al (Anticancer research, 2005, vol. 25, pp. 715-724).
Matzinger, Annual Review of Immunology, 1994, vol. 12, pp. 991-1045.
Bohm et al, Journal of Investigative Dermatology, 2001, vol. 117, pp. 132-140.
Jones et al (Advanced Drug Delivery Reviews 1998, vol. 31, pp. 153-170.
Ko et al (Food and Chemical Toxicology, 2000, vol. 38, pp. 861-865).
Biragyn et al., “Toll-Like Receptor 4-Dependent Activation of Dendritic Cells by β-Defensin 2,”Science, 2002, 298:1025-1029.
Bloom et al., “Identification of Tyrosinase-related Protein 2 as a Tumor Rejection Antigen for the B16 Melanoma,”J. Exp. Med., 1997, 185(3):453-460.
Bowman et al., “Stat3-mediated Myc expression is required for Src transformation and PDGF-induced mitogenesis,”Proc. Natl. Acad. Sci. USA, 2001, 98(13):7319-7324.
Bowman et al., “STATs in oncogenesis,”Oncogene, 2000, 19:2474-2488.
Bromberg and Darnell Jr., “The role of STATs in transcriptional control and their impact on cellular function,”Oncogene, 2000, 19:2468-2473.
Bromberg et al., “Stat3 as an oncogene,”Cell, 1999, 98(3):295-303, Erratum inCell, 1999, 99(2):239, Abstract only.
Caldenhoven et al., “STAT3β, a Splice Variant of Transcription Factor STAT3, Is a Dominant Negative Regulator of Transcription,”J. Biol. Chem., 1996, 271(21):13221-13227.
Catlett-Falcone et al., “Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells,”Immunity, 1999, 10(1):105-115.
Celluzzi and Falo Jr., “Cutting Edge: Physical Interaction Between Dendritic Cells and Tumor Cells Results in an Immunogen That Induces Protective and Therapeutic Tumor Rejection,”J. Immunol., 1998, 160:3081-3085.
De Bruijn et al., “Peptide loading of empty major histocompatibility complex molecules on RMA-S cells allows the induction of primary cytotoxic T lymphocyte responses,”Eur. J. Immunol., 1991, 21(12):2963-2970.
De Bruijn et al., “Phagocyte-induced antigen-specific activation of unprimed CD8+T cells in vitro,”Eur. J. Immunol., 1995, 25(5):1274-1285.
De Bruijn et al., “Mechanisms of induction of primary virus-specific cytotoxic T lymphocyte responses,”Eur. J. Immunol., 1992, 22(11):3013-3020.
Darnell Jr., “STATs and Gene Regulation,”Science, 1997, 277:1630-1635.
Darnell Jr. et al., “Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins,”Science, 1994, 264(5164):1415-1421.
Dranoff et al., “Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity,”Proc. Natl. Acad. Sci. USA, 1993, 90:3539-3543.
Fearon and Locksley, “The instructive role of innate immunity in the acquired immune response,”Science, 1996, 272(5258):50-53.
Fuchs and Matzinger, “Is cancer dangerous to the immune system?”Semin. In Immunol., 1996, 8:271-280.
Fujii et al., “Functional dissection of the cytoplasmic subregions of the IL-2 receptor βc chain in primary lymphocyte populations,”EMBO J., 1998, 17(22):6551-6557.
Gabrilovich et al., “Vascular Endothelial Growth Factor Inhibits the Development of Dendritic Cells and Dramatically Affects the Differentiation of Multiple Hematopoietic Lineages In Vivo,”Blood, 1998, 92(11):4150-4166.
Gabrilovich et al., “Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells,”Nat. Med., 1996, 2(10):1096-1103, Erratum inNat. Med., 1996, 11:1267, Abstract only.
Gallucci et al., “Natural adjuvants: endogenous activators of dendritic cells,”Nat. Med., 1999, 5(11):1249-1255.
Gong et al., “Induction of Antitumor activity by immunization with fusions of dendritic and carcinoma cells,”Nat. Med., 1997, 3(5):558-561.
Grandis et al., “Constitutive activation of Stat3 signaling abrogates apoptosis in squamous cell carcinogenesis in vivo,”Proc. Natl. Acad. Sci. USA, 97(8):4227-4232.
Greenberg,Basic and Clinical Immunology, 1987, 6thed., Stites et al. (eds.), Chapter 14, pp. 186-196.
Greenberg et al.,Basic and Clinical Tumor Immunology, 1983, Herbermann et al. (eds.), pp. 301-335.
Guo et al., “Effective tumor vaccine generated by fusion of hepatoma cells with activated B cells,”Science, 1994, 263(5146):518-520.
Hadden, “T-cell adjuvants,”Int. J. Immunopharmacol., 1994, 16(9):703-710.
Han et al., “Molecular Role of TGF-β, Secreted from a New Type of CD4+Suppressor T cell, NY4.2, in the Prevention of Autoimmune IDDM in NOD Mice,”J. Autoimmunity, 1997, 10(3):299-307.
Houbiers et al., “In vitro induction of human cytotoxic T lymphocyte responses against peptides of mutant and wild-type p53,”Eur. J. Irnmunol., 1993, 23(9):2072-2077.
Inaba et al., “Direct Activation of CD8+Cytotoxic T Lymphocytes by Dendritic Cells,”J. Exp. Med., 1987, 166:182-194.
Janeway Jr., “Approaching the asymptote: Evolution and revolution in immunology,”Cold Spring Harb. Symp. Quant. Biol., 1989, 54 Pt 1:1-13.
Kadowaki et al., “Natural Interferon α/β-producing Cells Link Innate and Adaptive Immunity,”J. Exp. Med., 2000, 192(2):219-225.
Kaplan et al., “Demonstration of an interferon γ-dependent tumor surveillance system in immunocompetent mice,”Proc. Natl. Acad. Sci. USA, 1998, 95:7556-7561.
Korpelainen et al., “Endothelial receptor tyrosine kinases activate the STAT signaling pathway: m
Jove Richard
Pardoll Drew
Yu Hua
Canella Karen A
Fish & Richardson P.C.
Johns Hopkins University
University of South Florida
LandOfFree
Stat3 antagonists and their use as vaccines against cancer does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Stat3 antagonists and their use as vaccines against cancer, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Stat3 antagonists and their use as vaccines against cancer will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4109224